医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Sonic Healthcare Selects Translational Software’s Pharmacogenomics Platform to Advance Precision Medicine in Australia

2018年07月10日 PM10:00
このエントリーをはてなブックマークに追加


 

BELLEVUE, Wash.

Translational Software®, Inc. (TSI), a global leader in the intelligent use of genetic data for clinical decision support, has finalized an agreement with Sonic Genetics, a member of Sonic Healthcare, one of the world’s largest medical diagnostics companies, to provide pharmacogenomic (PGx) decision support for lab testing services in Australia. PGx testing assesses an individual’s genomic markers to predict clinical response to specific medications to help clinicians more closely tailor personalized treatment.

Sonic Genetics chose to partner with TSI based on its robust knowledge-base of actively curated, evidence-based PGx content. TSI’s proprietary knowledge platform provides flexible reporting, genomic decision support and critical alerts regarding drug efficacy, toxicity and known interactions to guide clinical decision-making and enable physicians to prescribe the most effective medications. With clinical reporting for 65 genes, TSI’s PGx platform can be tailored to a variety of clinical specialties including cardiovascular, psychiatric, pain, internal medicine and geriatrics. Most importantly, TSI’s platform is rigorously curated and continually updated to prevent alert fatigue by only surfacing information that has the highest levels of evidence.

Sonic Genetics is at the forefront of providing comprehensive genetic testing services, offering thousands of genetic tests to support the optimal management of patient care, with laboratories across Australia, UK, Europe and USA. “We are pleased to extend our genetic testing services with Translational Software’s PGx platform to help clinicians ensure more precise patient treatment,” stated Dr. Colin Goldschmidt, CEO and managing director at Sonic Healthcare Limited. “We look forward to collaborating with a leading genomic data pioneer like TSI to offer the widest range of genetic testing services possible for our clients in Australia to advance the adoption of precision medicine and improve healthcare outcomes.”

TSI’s solutions empower customers to offer scalable and cost-effective precision medicine services. In addition to the most comprehensive and flexible PGx reporting solution available, the company offers an API that enables software providers to quickly expand their applications with PGx-based knowledge. With this powerful foundation, TSI is aligning with industry thought leaders such as Sonic Healthcare to help bring PGx closer to the point of care.

“Expanding the availability of PGx testing for clinicians is an essential first step for ensuring the integration of precision medicine into clinical practice,” stated Don Rule, CEO of TSI. “We are excited to work with Sonic Healthcare to help inform safer and more effective treatment decisions for its customers and their patients in Australia.”

About Sonic Healthcare:

Sonic Healthcare (www.sonichealthcare.com.au) is an international medical diagnostics company, offering extensive laboratory medicine/pathology and radiology services to the medical community. With 33,000 employees around the world, Sonic Healthcare is recognised for quality and service excellence, innovative technology, commitment to staff and continuing financial strength. Sonic Healthcare is represented in Australia, New Zealand, United Kingdom, Germany, Switzerland, Belgium, Ireland and the USA. The global head office of Sonic Healthcare is in Sydney, Australia.

About Translational Software, Inc.

Translational Software enables healthcare providers to realize the promise of precision medicine. We simplify complex genetic data into evidence-based actionable recommendations to deliver genomic decision support in platform agnostic formats. Our PGx knowledge base and Fast Healthcare Interoperability Resource (FHIR)-based API has been used to provide over one million PGx recommendations. To learn more visit us at www.TranslationalSoftware.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005271/en/

CONTACT

Myla Wagner Public Relations for Translational Software, Inc.
Myla
Wagner, 925-736-7515
myla@mylawagnerpr.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications
  • Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD
  • Tilray®宣布成立国际顾问委员会
  • 武田和纽约科学院宣布2019年度科学创新者奖获奖人
  • AMRA、身体組成の非侵襲的測定を実現する磁気共鳴診断ソフトウエアアプリケーションのAMRA® Profilerで米国FDAの承認を取得